Jump to: Authorized Access | Attribution | Authorized Requests

Study Description

Adverse effects of the coronavirus disease 2019 (COVID19) pandemic on US society, health, and economy are widespread. The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) aims to advance our knowledge on the impact of the COVID-19 pandemic in the United States. C4R is a diverse national prospective study comprising 14 long-standing prospective cohort studies and over 49,000 participants with extensive pre-COVID-19 phenotype data. C4R links pre-pandemic data on clinical and subclinical diseases and their risk factors, including behavior, cognition, biomarkers, and social determinants of health, to information on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute and post-acute COVID-related illness. Ascertainment of COVID-19 infection occurs via standardized questionnaires, adjudication of COVID-related hospitalizations and deaths, and SARS-CoV-2 serosurvey via dried blood spot cards. C4R is investigating the following research questions: 1) how pre-existing health conditions affect risk of severe or prolonged COVID-19 related illness; 2) how SARS-CoV-2 infection and COVID-19 illness affect long-term health; and 3) how the pandemic has affected health-related behaviors and non-COVID health outcomes. This resource will allow evaluation of risk and resilience factors for COVID-19 severity and long-term health effects.

Cohort Description

The Severe Asthma Research Program (SARP) has been investigating the clinical, physiologic and molecular phenotypes of asthma since 2000. It is currently following ~400 deeply phenotyped asthma patients.

Data Being Submitted

  • Wave 1 questionnaire data includes 397 variables for up to 375 SARP participants in C4R.
  • Wave 2 questionnaire data includes 448 variables for up to 289 SARP participants in C4R.
  • Dried Blood Spot/Serosurvey data includes 7 variables for up to 290 SARP participants in C4R.
  • Derived data includes 43 variables for up to 463 SARP participants in C4R.
  • Phenotype data includes 113 variables for up to 463 SARP participants in C4R.

Authorized Access
Publicly Available Data
  Link to other NCBI resources related to this study
Study Inclusion/Exclusion Criteria

Please see phs002788.

Study History

Please see phs002788.

Selected Publications
Diseases/Traits Related to Study (MeSH terms)
Authorized Data Access Requests
Study Attribution
  • Principal Investigator
    • Elizabeth C. Oelsner, MD, MPH. Columbia University Irving Medical Center, New York, NY, USA.
  • Co-Principal Investigator
    • R. Graham Barr, MD, DrPH. Columbia University Irving Medical Center, New York, NY, USA.
  • Co-Investigator
    • Pallavi Balte, MBBS, MPH, PhD. Columbia University Irving Medical Center, New York, NY, USA.
  • Cohort Principal Investigators
    • Victor Ortega, MD, PhD. Mayo Clinic, Phoenix, AZ, USA.
    • Sally Wenzel, MD. University of Pittsburgh, PA, USA.
  • Cohort Co-Investigator
    • David Mauger, PhD. Penn State University, Hershey, PA, USA.